INOVIO PHARMACEUTICALS, INC. Deferred Tax Assets, Deferred Income
INOVIO PHARMACEUTICALS, INC. (INO) had Deferred Tax Assets, Deferred Income of $0 as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2025-03-18
- 2024-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2023-12-31: Deferred Tax Assets, Deferred Income $22.00K.
- 2022-12-31: Deferred Tax Assets, Deferred Income $538.00K.
- 2021-12-31: Deferred Tax Assets, Deferred Income $987.00K.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2023-12-31 | $22.00K 10-K · filed 2025-03-18 |
| 2022-12-31 | $538.00K 10-K · filed 2024-03-06 |
| 2021-12-31 | $987.00K 10-K · filed 2023-03-01 |
| 2020-12-31 | $1.63M 10-K · filed 2022-03-01 |
| 2019-12-31 | $1.51M 10-K · filed 2021-03-01 |
| 2018-12-31 | $985.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | $297.00K 10-K · filed 2019-03-12 |
| 2016-12-31 | $5.45M 10-K · filed 2018-03-14 |
| 2015-12-31 | $5.21M 10-K · filed 2017-03-15 |
| 2014-12-31 | $1.83M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |